Thanks, Mike. Good morning, everyone. I’ll start with our investment activity for the third quarter, and then provide an update on our portfolio. New investment fundings during the third quarter were approximately $110 million across 40 portfolio companies, including $52 million in 2 new companies and $57 million in add-ons to existing investments. Sales and repayment activity totaled approximately $103 million, resulting in a net-funded portfolio growth of $7 million quarter-over-quarter. This quarter, we remain focused on investing in first lien senior secured loans with 93% of our new investment fundings within first lien structures and 7% in equity investments. Our new investment fundings were comprised of a mix between new and existing companies, representing 48% and 52%, respectively. Across our new portfolio companies this quarter, we leveraged Bain Capital’s in-house industry knowledge and expertise. Our largest new investment was a first lien senior secured loan to Forward Slope, a provider of mission-critical software and surveillance solutions to the defense industry. We sourced this investment from a sponsor who has a value-oriented approach, which strong experience in aerospace and defense, and who valued our prior experience working with them in this sector. Aerospace and defense is our largest sector exposure and one that we continue to favor in the current environment, given it does not generally cycle with the macro-economy. Another notable new investment this quarter was the first lien senior secured loan and equity co-investment to HealthDrive, a provider of a comprehensive suite of on-site medical services to patients in skilled nursing facilities. While we have shied away from many of the healthcare position practice management roll-ups in recent years, we are now focused on finding attractive spots in the healthcare sector. Our investment thesis for HealthDrive centered on the solid fundamental industry dynamics, which are underpinned by non-discretionary services. The company’s attractive financial profile demonstrating higher retention rates and partnering with a well-capitalized healthcare focused sponsor. Turning now to the investment portfolio, at the end of the third quarter, the size of our investment portfolio at fair value was approximately $2.4 billion across a highly diversified set of 143 portfolio companies operating across 30 different industries. Our portfolio primarily consists of investments in first lien senior secured loans given our focus on downside management and investing in the top of the capital structure. As of September 30, 64% of the investment portfolio at fair value was invested in first lien debt, 4% in second lien debt, 2% in subordinated debt, 4% in preferred equity, 11% in equity and other interests, and 15% across our joint ventures. As we have highlighted to our shareholders in prior earnings calls, the decline in our stated first lien exposure is driven by the growth in our joint ventures. Notably, 94% of the underlying investments held in these investment vehicles consist of first lien loans, resulting in a look through first lien exposure of approximately 82% of the portfolio. As of September 30, 2023, the weighted average yield on the investment portfolio at amortized costs and fair value were 12.9% and 13.1%, respectively, as compared to 12.8% and 13% as of June 30, 2023. The increase was primarily driven by higher reference rates on our loans. And as a reminder, 94% of our debt investments bear interest at a floating rate. Moving on to portfolio credit quality trends, they were stable quarter-over-quarter. Within our internal risk rating scale, we saw an improvement within our risk rating 1 and 2 investments, which indicates that a company was performing in line or better than expectation relative to our initial underwrite. As of September 30, these investments comprised 95% of our portfolio at fair value, up from 91% as of the prior quarter end. Risk rating 3 and 4 investments comprised 5% of our portfolio at fair value, down from 8.5% as of Q2. Investments on non-accrual are 1.5% and 1.0% of the total investment portfolio at amortized cost and fair value, respectively, as compared to 2.1% and 0% as of June 30. We believe our non-accrual rates are among the lowest level across the BDC sector. Credit fundamentals remain solid in our portfolio, with the median leverage of 5.0 terms as of September 30, as compared to 5.1 times as of June 30. Sally will now provide a more detailed financial review.